ストックスクリーナーアプリを入手
7.35
0.81%
-0.06
アフターアワーズ：
29.72
22.37
+304.35%
前日終値:
$7.41
開ける：
$7.49
24時間の取引高:
719.36K
Relative Volume:
0.42
時価総額：
$770.93M
収益：
-
当期純損益:
$-57.39M
株価収益率:
-5.0007
EPS:
-1.4698
ネットキャッシュフロー:
$-45.79M
1週間 パフォーマンス:
+1.52%
1か月 パフォーマンス:
+5.15%
6か月 パフォーマンス:
+192.83%
1年 パフォーマンス:
+1,818%
1日の値動き範囲:
$7.175
$7.63
1週間の範囲:
$7.085
$7.805
52週間の値動き範囲:
$0.3233
$7.94
Relmada Therapeutics Inc Stock (RLMD) Company Profile
名前
Relmada Therapeutics Inc
セクター
電話
646 876 3459
住所
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, GOODO, SHMD, PSNYW, DWLD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.485 | 3.18B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.29 | 306.92M | 52.15M | -21.46M | 0 | -0.4675 |
PSNYW
Polestar Automotive Holding Uk
|
3.09 | 271.04M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.06 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | 開始されました | Piper Sandler | Overweight |
| 2026-01-23 | 再開されました | Leerink Partners | Outperform |
| 2025-12-22 | 開始されました | Jefferies | Buy |
| 2025-11-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-05 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-06-05 | ダウングレード | Goldman | Neutral → Sell |
| 2022-10-14 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-14 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-10-14 | ダウングレード | Truist | Buy → Hold |
| 2022-10-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 開始されました | Mizuho | Buy |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-10-28 | ダウングレード | Goldman | Buy → Neutral |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-04 | 開始されました | SunTrust | Buy |
| 2020-04-21 | 開始されました | Goldman | Buy |
| 2020-01-27 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
すべてを表示
Relmada Therapeutics Inc (RLMD) 最新ニュース
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - Investing News Network
Bladder cancer drug NDV-01 heads to AUA with Phase 3 on track - Stock Titan
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - GlobeNewswire Inc.
Commodore holds 5.5M RLMD shares, including 4.21M warrant shares (RLMD) - Stock Titan
Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect? - MSN
Relmada Therapeutics (RLMD) Stock Chart | Relmada Therapeutics Inc. posts 103% EPS miss vs estimatesReal Trader Network - UBND thành phố Hải Phòng
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect? - qz.com
Relmada Therapeutics Inc erwartet einen Verlust von 70 Cents pro AktieEarnings Preview - TradingView
Relmada Therapeutics (RLMD) Stock: Solid Choice? (Breakout Watch) 2026-04-20Investment Picks - Xã Châu Thành
Relmada (NASDAQ: RLMD) details 2025 turnaround, seeks share and plan increases - Stock Titan
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3%Here's What Happened - MarketBeat
Relmada Therapeutics shares jump 25% after promising bladder cancer trial results - MSN
Q3 2025 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Relmada Therapeutics (RLMD) price target increased by 59.26% to 14.62 - MSN
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat
Form PRE 14AOther preliminary proxy statements - ADVFN
[EFFECT] RELMADA THERAPEUTICS, INC. SEC Filing - Stock Titan
Shorts Report: Is Relmada Therapeutics Inc a speculative investmentGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale under 424B3 - Stock Titan
Relmada Therapeutics (NASDAQ:RLMD) Hits New 12-Month HighShould You Buy? - MarketBeat
Aug Update: Should I invest in Relmada Therapeutics Inc before earningsM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
Volume Recap: Does Relmada Therapeutics Inc offer margin of safety2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Report: Whats next for Relmada Therapeutics Inc stock2026 WrapUp & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Mizuho reiterates Relmada stock rating on Phase 3 trial progress By Investing.com - Investing.com Australia
Mizuho reiterates Relmada stock rating on Phase 3 trial progress - Investing.com UK
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider
Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD) - The Globe and Mail
Relmada (NASDAQ: RLMD) raises $100M, adds NDV-01 and sepranolone - Stock Titan
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
Can Relmada Therapeutics (RLMD) Stock Go Higher | Price at $6.94, Down 0.72%Investment Signal Network - Cổng thông tin điện tử Tỉnh Sơn La
RLMD SEC FilingsRelmada Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RLMD PE Ratio & Valuation, Is RLMD Overvalued - Intellectia AI
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement - Stock Titan
RLMD Stock Analysis: Relmada Therapeutics Inc slips 1.55% to $6.99 in biotech trading - UBND thành phố Hải Phòng
Relmada Therapeutics Inc. (US75955J4022.SG) analyst ratings, estimates and forecasts - Yahoo Finance UK
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength - The Globe and Mail
RLMD Stock Surges 42% in a Week: Here's What You Should Know - Eastern Progress
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha
With 20-plus years in drug development, Raj Pruthi joins PreveCeutical - Stock Titan
Relmada wins bullish view at Piper Sandler on cancer therapy - MSN
Relmada Therapeutics Inc (RLMD) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):